In Vitro Activity of Novel Lipopeptides against Triazole-Resistant <i>Aspergillus fumigatus</i>
2022
Simona Fioriti | Oscar Cirioni | Oriana Simonetti | Lucia Franca | Bianca Candelaresi | Francesco Pallotta | Damian Neubauer | Elzbieta Kamysz | Wojciech Kamysz | Benedetta Canovari | Lucia Brescini | Gianluca Morroni | Francesco Barchiesi
Aspergillosis, which is mainly sustained by <i>Aspergillus fumigatus</i>, includes a broad spectrum of diseases. They are usually severe in patients with co-morbidities. The first-line therapy includes triazoles, for which an increasing incidence of drug resistance has been lately described. As a consequence of this, the need for new and alternative antifungal molecules is absolutely necessary. As peptides represent promising antimicrobial molecules, two lipopeptides (C14-NleRR-NH<sub>2</sub>, C14-WRR-NH<sub>2</sub>) were tested to assess the antifungal activity against azole-resistant <i>A. fumigatus</i>. Antifungal activity was evaluated by determination of minimum inhibitory concentrations (MICs), time–kill curves, XTT assay, optical microscopy, and checkerboard combination with isavuconazole. Both lipopeptides showed antifungal activity, with MICs ranging from 8 mg/L to 16 mg/L, and a dose-dependent effect was confirmed by both time–kill curves and XTT assays. Microscopy showed that hyphae growth was hampered at concentrations equal to or higher than MICs. The rising antifungal resistance highlights the usefulness of novel compounds to treat severe fungal infections. Although further studies assessing the activity of lipopeptides are necessary, these molecules could be effective antifungal alternatives that overcome the current resistances.
显示更多 [+] 显示较少 [-]